Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics
Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (<i>RET</i>) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely alter its pharmacokinetics (PK). Mild HI ha...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI AG
2024-04-01
|
| Серии: | Pharmaceutics |
| Предметы: | |
| Online-ссылка: | https://www.mdpi.com/1999-4923/16/4/564 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|